Straumann Holding AG (OTCMKTS:SAUHY - Get Free Report) was the recipient of a significant decline in short interest in the month of October. As of October 15th, there was short interest totaling 26,983 shares, a decline of 39.9% from the September 30th total of 44,911 shares. Based on an average daily trading volume, of 255,560 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.0% of the company's shares are short sold.
Wall Street Analyst Weigh In
Several brokerages have recently commented on SAUHY. Citigroup reaffirmed a "sell" rating on shares of Straumann in a research report on Wednesday, October 21st. UBS Group raised shares of Straumann from a "neutral" rating to a "buy" rating in a research note on Tuesday, September 1st. Deutsche Bank Aktiengesellschaft lowered shares of Straumann from a "buy" rating to a "hold" rating in a research note on Friday, August 21st. The Goldman Sachs Group upgraded shares of Straumann from a "neutral" rating to a "buy" rating in a report on Monday, September 14th. Finally, Berenberg Bank raised shares of Straumann to a "strong-buy" rating in a research note on Thursday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy".
Check Out Our Latest Stock Report on SAUHY
Straumann Stock Up 0.6%
Shares of OTCMKTS:SAUHY opened at $11.79 on Friday. Straumann has a twelve month low of $9.44 and a twelve month high of $13.61. The stock's 50 day moving average is $11.42 and its 200-day moving average is $11.66.
About Straumann
(
Get Free Report)
Straumann Group is a Switzerland-based dental technology company headquartered in Basel. Founded in 1954, the company develops, manufactures and distributes products used in tooth replacement, restorative dentistry and oral tissue regeneration. Its offerings are designed for dental professionals, laboratories and patients across a range of clinical applications.
The company's portfolio includes dental implants, implant-supported prosthetics, biomaterials for bone and tissue regeneration, orthodontic aligners and digital dentistry solutions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Straumann, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Straumann wasn't on the list.
While Straumann currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.